Morgan Stanley
RLAY icon

Morgan Stanley’s Relay Therapeutics RLAY Stock Holding History

Morgan Stanley’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.1M Buy
3,851,071
+2,419,068
+169% +$35.1M ﹤0.01% 1856
2026
Q1 		$14.2M Sell
1,432,003
-586,461
-29% -$5.25M ﹤0.01% 3265
2025
Q4 		$17.1M Buy
2,018,464
+254,368
+14% +$1.82M ﹤0.01% 3079
2025
Q3 		$9.21M Buy
1,764,096
+341,750
+24% +$1.3M ﹤0.01% 3616
2025
Q2 		$4.92M Sell
1,422,346
-170,840
-11% -$508K ﹤0.01% 4076
2025
Q1 		$4.17M Buy
1,593,186
+292,416
+22% +$1.15M ﹤0.01% 4077
2024
Q4 		$5.36M Buy
1,300,770
+338,659
+35% +$1.84M ﹤0.01% 3930
2024
Q3 		$6.81M Sell
962,111
-280,167
-23% -$2.09M ﹤0.01% 3711
2024
Q2 		$8.1M Buy
1,242,278
+85,257
+7% +$583K ﹤0.01% 3475
2024
Q1 		$9.6M Buy
1,157,021
+428,317
+59% +$4.18M ﹤0.01% 3381
2023
Q4 		$8.02M Buy
728,704
+71,163
+11% +$600K ﹤0.01% 3534
2023
Q3 		$5.53M Sell
657,541
-119,926
-15% -$1.29M ﹤0.01% 3663
2023
Q2 		$9.76M Buy
777,467
+215,333
+38% +$2.68M ﹤0.01% 3187
2023
Q1 		$9.26M Sell
562,134
-1,807,210
-76% -$32.4M ﹤0.01% 3219
2022
Q4 		$35.4M Buy
2,369,344
+2,027,003
+592% +$38.8M ﹤0.01% 1805
2022
Q3 		$7.66M Sell
342,341
-283,783
-45% -$6.23M ﹤0.01% 3250
2022
Q2 		$10.5M Buy
626,124
+194,644
+45% +$4.17M ﹤0.01% 3023
2022
Q1 		$12.9M Sell
431,480
-92,013
-18% -$2.23M ﹤0.01% 2597
2021
Q4 		$16.1M Buy
523,493
+76,702
+17% +$2.42M ﹤0.01% 2399
2021
Q3 		$14.1M Sell
446,791
-122,854
-22% -$4.14M ﹤0.01% 2499
2021
Q2 		$20.8M Buy
569,645
+79,037
+16% +$2.6M ﹤0.01% 2106
2021
Q1 		$17M Buy
490,608
+361,849
+281% +$15.7M ﹤0.01% 2089
2020
Q4 		$5.35M Buy
128,759
+24,434
+23% +$1.1M ﹤0.01% 3185
2020
Q3 		$4.44M Buy
+104,325
New +$3.98M ﹤0.01% 2826

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Morgan Stanley's RLAY Position: Q2 2026 in Review

Morgan Stanley increased its Relay Therapeutics (RLAY) stake by 169% in Q2 2026, buying an estimated $35.1M and bringing the position to 3,851,071 shares worth $72.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Morgan Stanley first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Morgan Stanley held 3,851,071 shares of Relay Therapeutics worth $72.1M as of Q2 2026.
  • Morgan Stanley bought 2,419,068 Relay Therapeutics shares in Q2 2026, an estimated $35.1M.
  • Relay Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1856 holding.
  • Morgan Stanley first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.